Skip to main content

Drug-Coated Balloon Therapy — Optilume

Optilume® (Urotronic, Inc.) is a paclitaxel-coated drug-coated balloon (DCB) — the only FDA-approved antimitotic device for urethral stricture disease. It combines mechanical urethral dilation with localized paclitaxel delivery to inhibit fibrosis and reduce stricture recurrence. The AUA Urethral Stricture Disease Guideline Amendment 2023 recommends its use for recurrent bulbar urethral strictures <3 cm in patients who have failed prior DVIU or dilation.[1][2]

This article is the device-level deep-dive: mechanism and preclinical tissue pharmacology, the complete ROBUST trial program (I / III with 5-year and 3-year extensions), procedural technique, off-label use patterns from the Sugrue 2026 international survey, and device-specific safety including the Gao 2025 pudendal-artery case. For the class-level comparison against MMC, HA/CMC, PRP, and other adjuncts, see Antimitotics & antifibrotics. For the clinical condition, see Urethral stricture.

Device description and mechanism​

The Optilume DCB is a urethral dilation balloon coated with paclitaxel — a microtubule-stabilizing taxane that produces antiproliferative and antifibrotic effects by preventing cell division, inhibiting fibroblast proliferation, and reducing collagen deposition.[2][3]

Preclinical tissue pharmacology​

  • Will 2011 — paclitaxel 10–100 nM significantly inhibits urinary-tract smooth-muscle cell proliferation and type III collagen production without cytotoxicity to smooth-muscle cells[3]
  • Barbalias 2018 rabbit urethral model — paclitaxel distributes to all urethral layers (urothelial, submucosal, and smooth-muscle) immediately after DCB inflation; drug and mild inflammation persist at 24 and 48 hours[4]
  • Liourdi 2015 porcine ureteral model — paclitaxel penetrates through urothelium to submucosa and muscle by 12–24 hours, with reduced inflammation compared to conventional balloon dilation[5]

The dual mechanism — immediate mechanical dilation for symptom relief combined with sustained local drug delivery to prevent fibrotic recurrence — is what distinguishes the DCB from plain balloon dilation or DVIU.[2]

Available sizes​

Multiple sizes exist; the 24F/3 cm DCB has been associated with higher recurrence rates in real-world data (see below).[6]

ROBUST I — single-arm long-term durability​

Timepointn evaluableFunctional successFreedom from reinterventionIPSS (baseline → f/u)Qmax change
2 y4670%—25.2 → 6.9 (p < 0.0001)Significant ↑[7]
3 y4367%77%25.2 → 5.5 (p < 0.0001)Significant ↑[8]
5 y4358%71.7% (KM)25.2 → 7.2 (p < 0.001)5.0 → 19.9 mL/s (p < 0.01)[9]

Cohort profile: men with recurrent bulbar strictures ≤2 cm (mean 1.7 prior dilations; 43% with >1 prior dilation). At 5 years, Optilume maintained 71.7% freedom from repeat intervention. Erectile function was unaffected throughout and no serious treatment-related AEs were observed across the entire 5-year study period.[9]

ROBUST III — pivotal multicenter RCT​

The pivotal multicenter single-blind RCT that supported FDA approval.[10]

Design​

  • 127 patients at 22 sites; recurrent anterior strictures ≤3 cm, ≤12F, ≥2 prior endoscopic treatments, IPSS ≥11, Qmax <15 mL/s
  • Randomized to Optilume DCB vs standard endoscopic treatment (DVIU or dilation)

Outcomes​

EndpointOptilume DCBControlp
Anatomical success at 6 mo (≥14F)75%27%0.001
Freedom from reintervention at 1 y83.2%21.7%<0.001
Freedom from reintervention at 3 y71%——

3-year extension (Srikanth 2025)[11]​

  • DCB arm maintained 71% freedom from reintervention at 3 years — nearly equal to the 2-year data and ~3× the control at 1 year
  • Clinically significant subgroups (≥5 prior dilations, strictures ≥2 cm) showed no differential outcome
  • Crossover cohort (control patients who failed standard treatment and opted for DCB) produced a Kaplan-Meier curve closely resembling the original DCB cohort — supports the treatment effect

AUA guideline positioning​

AUA 2023 Urethral Stricture Disease Guideline Amendment, Statement 11b: "Surgeons may perform urethral dilation, or direct visual internal urethrotomy, combined with drug-coated balloons, for recurrent bulbar urethral strictures <3 cm."[1]

Key restrictions from the guideline:

  • Restricted to recurrent disease (prior DVIU / dilation failure)
  • Anterior / bulbar only — not FDA-approved for posterior / bladder-neck stenoses (off-label use is common in real-world data; see below)
  • ≤3 cm length — longer strictures were underrepresented in ROBUST III
  • No data on repeat use — repeated DCB application has not been validated

Procedural technique​

Based on ROBUST protocols and the FIRST-CARE trial design:[17][13]

StepDetail
AnesthesiaGeneral (58% in the Sugrue 2026 survey) or local / sedation
CystoscopyConfirm stricture location and length
Pre-dilationTo ~20F using a standard balloon or sequential dilators
Optilume inflationPosition across the stricture; 30F at 10 bar for ≥5 minutes (per the FIRST-CARE protocol) or per manufacturer instructions
Post-procedure catheter12–14F Foley for 3–5 days
Follow-upUroflowmetry, IPSS, cystoscopy per institutional protocol

Practice-variation signal — Sugrue 2026​

International survey of 102 Optilume users revealed significant practice variation in catheter duration, perioperative antibiotic use, and postprocedure contraception advice — reflecting the early-adoption phase of this technology.[13]

Off-label use in real-world data​

The Sugrue 2026 survey (n = 102) documents widespread off-label use of Optilume beyond the AUA-approved indication:[13]

Off-label use% of surveyed urologists
Penile urethral strictures65%
Primary / first-line treatment64%
Bladder-neck stenoses65%

Higher-volume users (≥10 / y) were more likely to perform DCB under flexible cystoscopy (OR 5.14), for bladder-neck strictures (OR 4.66), and for recurrences (OR 6.92).[13]

Posterior urethral stenosis (BNC / VUAS)​

Berg 2025 retrospective comparative study (n = 141) — DCB dilation significantly improved recurrence-free survival vs standard endoscopic treatment (p = 0.013); treatment modality confirmed as significant predictor on multivariate analysis (HR 0.40; 95% CI 0.19–0.87; p = 0.021). Qmax improved from 9 → 22 mL/s (p = 0.001).[14]

Membranous / sphincteric strictures​

Jelisejevas 2025 (n = 53 — 35 membranous strictures, 18 VUAS extending into the sphincter) — Optilume DCB dilation produced 66.6% freedom from recurrence at median 13.3-month follow-up with no de novo incontinence, an important finding given the proximity to the external urethral sphincter.[12]

Penile urethral strictures​

Salem 2025 small multicenter series (n = 8) — median IPSS 25.5 → 5.0 (p < 0.01); off-label use, not FDA-approved.[15]

Real-world 319-patient TURNS experience​

Patel 2025 — anterior strictures 78.4% and posterior stenoses 75.8% 1-year recurrence-free survival. Independent predictors of recurrence:[6]

  • Strictures after hypospadias repair — HR 5.21 (95% CI 1.06–25.6; p = 0.042)
  • 24F/3 cm DCB use — HR 3.64 (95% CI 1.10–12.09; p = 0.035)

Anatomical recurrence-free survival was lower than functional (66.4% anterior / 59.4% posterior) — some patients tolerate mild anatomical recurrence without functional impairment.[6]

FIRST-CARE — the pending first-line RCT​

FIRST-CARE (NCT06827210) — multicenter, single-blind RCT enrolling 140 treatment-naïve patients with single bulbar urethral strictures ≤3 cm to evaluate Optilume DCB as first-line treatment vs standard endoscopic management. Primary endpoint: freedom from repeat intervention at 12 months. This trial directly addresses the first-line-use evidence gap; results are anticipated to reshape the AUA algorithm.[17]

Safety profile​

ConcernEvidence
Common AEsUTI, post-procedural hematuria, dysuria — generally mild and self-limited[9][10]
Serious treatment-related AEsNone reported in ROBUST I through 5 years; rare in ROBUST III[9][10]
Erectile functionUnaffected across all ROBUST trials through 5 years[9][11]
ContinenceNo de novo incontinence in the Jelisejevas 2025 sphincteric-stricture series[12]
Rare vascular injuryOne case report (Gao 2025) of recurrent massive urethral bleeding requiring selective embolization of the internal pudendal artery after Optilume use in a post-urethroplasty recurrence[16]
Systemic paclitaxel concernsLocal delivery minimizes systemic exposure; no systemic paclitaxel-related toxicity reported[4][5]
ContraceptionPractice varies in the Sugrue 2026 survey; some centers advise post-procedure contraception due to paclitaxel exposure; no standardized guidance exists[13]

Limitations and unanswered questions​

Several key evidence gaps remain:[2][6][13]

  • Durability in complex or longer strictures (>3 cm) is uncertain
  • Repeated DCB use has not been validated and is not recommended by the AUA
  • Post-urethroplasty recurrence — the role of DCB as salvage therapy requires further investigation (the Gao 2025 bleeding case occurred in this setting)
  • Penile urethral strictures — the ROBUST III trial was not powered for this subgroup; off-label use is common but unvalidated
  • First-line use — awaiting FIRST-CARE results
  • Cost-effectiveness — described as "cost-effective" in reviews, but formal health-economic comparisons vs urethroplasty and repeated DVIU are limited
  • Long-term oncologic safety — theoretical concern regarding paclitaxel's effects on urethral tissue over decades; no malignant transformation observed to date

Evidence Summary​

DomainEvidence levelKey source
FDA approval / guidelineLevel 1 guidelineAUA 2023 amendment Statement 11b[1]
Pivotal RCTLevel 1ROBUST III — Elliott 2022[10]; Srikanth 2025 3-year[11]
5-year single-arm durabilityLevel 2DeLong 2025 ROBUST I 5-year[9]
Preclinical tissue PKPreclinicalWill 2011[3]; Barbalias 2018[4]; Liourdi 2015[5]
Posterior stenosis (off-label)Level 3 (comparative retrospective)Berg 2025[14]
Membranous / sphincteric (off-label)Level 3Jelisejevas 2025[12]
Penile strictures (off-label)Level 4 (small series)Salem 2025[15]
Real-world 319-patient cohortLevel 3Patel 2025 TURNS[6]
Practice-pattern surveyLevel 4Sugrue 2026[13]
Pending first-line RCTOngoingFIRST-CARE protocol[17]
Vascular-injury caseLevel 5Gao 2025[16]

Clinical Positioning​

  • Optilume is the FDA-approved antimitotic device for recurrent bulbar urethral strictures <3 cm with prior DVIU / dilation failure. Outside this label, use is off-label and should be documented with explicit informed consent.[1]
  • ROBUST I 5-year data establish durability — 71.7% freedom from reintervention at 5 years in recurrent bulbar strictures with preserved erectile function and no serious treatment-related AEs.[9]
  • ROBUST III 3-year data confirm efficacy translation from the RCT to extended follow-up — 71% freedom from reintervention with consistent efficacy across stricture-severity subgroups.[10][11]
  • The 24F/3 cm DCB is a recurrence predictor in the Patel 2025 real-world cohort (HR 3.64) — avoid when possible in shorter strictures where a smaller device would suffice.[6]
  • Hypospadias-repair strictures respond poorly (HR 5.21 for recurrence) — counsel these patients explicitly.[6]
  • For posterior stenoses (BNC / VUAS) off-label use is widespread and has supportive retrospective data (Berg 2025, Jelisejevas 2025 with no de novo incontinence). This is a reasonable alternative where repeat DVIU has failed, but follow the AUA stance — DCB is not FDA-approved for this indication.[14][12]
  • Do not reflexively repeat DCB after initial failure — no validated data on retreatment and AUA does not endorse.[1]
  • For treatment-naïve bulbar strictures, continue standard DVIU / dilation until FIRST-CARE reports — DCB as first-line is common in practice but evidence-pending.[17][13]
  • Procedural essentials: pre-dilate to ~20F; inflate at 30F × 10 bar × ≥5 min; 12–14F Foley for 3–5 days.[17][13]
  • Counsel about the Gao 2025 case (rare massive urethral bleeding post-Optilume) particularly in post-urethroplasty recurrence — this is a legitimate but rare risk.[16]
  • Contraception advice is inconsistent in practice (Sugrue 2026); a reasonable default is short-term barrier contraception after the procedure given paclitaxel exposure.[13]
  • Practice-variation is a legitimate patient-counseling point — catheter duration, prophylaxis regimens, and follow-up protocols differ across high-volume centers.[13]

See Also​

References​

1. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. "Urethral stricture disease guideline amendment (2023)." J Urol. 2023;210(1):64–71. doi:10.1097/JU.0000000000003482

2. Kapriniotis K, Loufopoulos I, Apostolopoulou A, Anderson PCB, Papaefstathiou E. "Drug-coated balloon treatment for urethral strictures: is this the future? A review of the current literature." J Clin Med. 2025;14(8):2854. doi:10.3390/jcm14082854

3. Will TA, Polcari AJ, Garcia JG, et al. "Paclitaxel inhibits ureteral smooth-muscle cell proliferation and collagen production in the absence of cell toxicity." J Urol. 2011;185(1):335–340. doi:10.1016/j.juro.2010.09.006

4. Barbalias D, Lappas G, Ravazoula P, et al. "Evaluation of the distribution of paclitaxel after application of a paclitaxel-coated balloon in the rabbit urethra." J Endourol. 2018;32(5):381–386. doi:10.1089/end.2017.0935

5. Liourdi D, Kallidonis P, Kyriazis I, et al. "Evaluation of the distribution of paclitaxel by immunohistochemistry and nuclear magnetic resonance spectroscopy after the application of a drug-eluting balloon in the porcine ureter." J Endourol. 2015;29(5):580–589. doi:10.1089/end.2014.0683

6. Patel HV, Erickson BA, Abbasi B, et al. "Early real-world experience with Optilume drug-coated balloon for anterior urethral strictures and posterior urethral stenoses." Urology. 2025. doi:10.1016/j.urology.2025.10.025

7. Mann RA, Virasoro R, DeLong JM, et al. "A drug-coated balloon treatment for urethral stricture disease: two-year results from the ROBUST I study." Can Urol Assoc J. 2021;15(2):20–25. doi:10.5489/cuaj.6661

8. Virasoro R, DeLong JM, Estrella RE, et al. "A drug-coated balloon treatment for urethral stricture disease: three-year results from the ROBUST I study." Res Rep Urol. 2022;14:177–183. doi:10.2147/RRU.S359872

9. DeLong J, Virasoro R, Pichardo M, et al. "Long-term outcomes of recurrent bulbar urethral stricture treatment with the Optilume drug-coated balloon: five-year results from the ROBUST I study." J Urol. 2025;213(1):90–98. doi:10.1097/JU.0000000000004229

10. Elliott SP, Coutinho K, Robertson KJ, et al. "One-year results for the ROBUST III randomized controlled trial evaluating the Optilume drug-coated balloon for anterior urethral strictures." J Urol. 2022;207(4):866–875. doi:10.1097/JU.0000000000002346

11. Srikanth P, DeLong J, Virasoro R, Elliott SP. "A drug-coated balloon treatment for urethral stricture disease: three-year results from the ROBUST III study." J Endourol. 2025. doi:10.1089/end.2024.0718

12. Jelisejevas LA, Tulchiner G, Rehder P. "Optilume drug-coated balloon dilation for male sphincteric (membranous) urethral strictures: 53 consecutive cases." J Clin Med. 2025;14(23):8369. doi:10.3390/jcm14238369

13. Sugrue DD, O'Connor J, Białek Ł, et al. "Practices in urethral stricture management with drug-coated balloon dilatation: an international survey." World J Urol. 2026;44(1):285. doi:10.1007/s00345-026-06343-y

14. Berg EK, Mehmedovic S, Askari D, et al. "Efficacy of drug-coated balloon dilation vs endoscopic standard treatment in posterior urethral stenosis: a real-world comparative study." Urology. 2025. doi:10.1016/j.urology.2025.07.034

15. Salem J, Menendez-Suarez JJ, Tosev G, Borgmann H, Kuru T. "Efficacy and mid-term outcomes of paclitaxel-coated balloon (Optilume) for penile strictures." J Clin Med. 2025;14(17):6022. doi:10.3390/jcm14176022

16. Gao Y, Mukherjee S, Aydin A, Shekho M, Winkler M. "An unusual case of recurrent massive urethral bleeding following Optilume urethral dilatation needing selective embolisation of the bleeding vessel." Ann R Coll Surg Engl. 2025. doi:10.1308/rcsann.2025.0088

17. Mahdi MB, Haase RN, Sander L, et al. "Treatment of bulbar urethral strictures with Optilume drug-coated balloons in a previously untreated population (FIRST-CARE): protocol for a single-blind multicentre randomised controlled trial." BMJ Open. 2026;16(1):e103948. doi:10.1136/bmjopen-2025-103948